-

Veradigm Introduces Cardiometabolic Clinical Registry Datasets to Enhance the Next Generation of Real-World Research

With the introduction of seven new disease-specific registry datasets, Veradigm is enabling deep, targeted research to drive innovation and enhance real-world clinical insights

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today the launch of its disease-specific cardiometabolic Clinical Data Registry datasets, which contain de-identified information about patients' health and care for a specific condition or disease. These datasets provide researchers with access to specialty, Natural Language Processing (NLP)-enhanced real-world data to advance the understanding of patient insights and clinical details to support research throughout the drug development life cycle.

Veradigm’s Clinical Data Registries harmonize data from over 80 different electronic health records (EHRs) into a research ready data model, leveraging both structured and unstructured data to provide precise insights into disease patterns, treatment outcomes, and patient care.

Veradigm’s new cardiometabolic disease registry cohorts include:

  • Heart Failure Registry
  • Atrial Fibrillation Registry
  • ASCVD Registry
  • Hypertension Registry
  • Type 1 Diabetes Registry
  • Type 2 Diabetes Registry
  • Chronic Kidney Disease Registry

“Globally, cardiovascular disease and metabolic disorders are the number one leading cause of death,” said Stuart Green, Senior Vice President & General Manager of Life Sciences Business at Veradigm. “We’ve leveraged NLP to extract insights from unstructured and semi-structured clinical data to generate evidence, particularly looking for clinical details that are important for life science researchers, public health and government regulators.”

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.

© 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.

Contacts

Investors:
Jenny Gelinas
312-506-1237
jenny.gelinas@veradigm.com

Media:
Concetta Rasiarmos
630-740-3152
concetta.rasiarmos@veradigm.com

Veradigm

OTC Pink:MDRX

Release Versions
Hashtags

Contacts

Investors:
Jenny Gelinas
312-506-1237
jenny.gelinas@veradigm.com

Media:
Concetta Rasiarmos
630-740-3152
concetta.rasiarmos@veradigm.com

More News From Veradigm

Veradigm Provides Business and Strategy Update

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, is providing estimated financial performance for the fiscal year 2025 and key areas of strategic focus for 2026. “On my first investor call in October, I committed to advancing three strategic objectives in my first 100 days: reset our business strategy, recover our market leadership with independent physician practices and reignite profitable growth,” said...

Veradigm Brings Patient Voice to Healthcare Research with New Real-World Data Survey Solution

CHICAGO--(BUSINESS WIRE)--Veradigm (OTCMKTS:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced a new patient‑reported outcomes (PRO) survey capability that brings the patient voice directly into real‑world evidence generation. The new solution gives life sciences organizations timely, privacy‑preserving insights directly from patients, adding essential context to clinical and observational research. Built on Veradigm’s FollowMyHealth pat...

Veradigm to Release Business Update February 17th and Host Investor Call February 18th

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management plans to provide a business update after the close of regular stock market hours on February 17, 2026. Veradigm management plans to host an investor conference call and webcast to discuss the Company’s update at 8:00 a.m. Eastern Time on February 18, 2026. Update Call Details Veradigm plans to issue a press release after the c...
Back to Newsroom